Semaglutide Before and After: Month-by-Month

Setting Realistic Expectations

Semaglutide produces meaningful, clinically significant weight loss — but results vary based on starting weight, dose achieved, adherence, lifestyle factors, and individual physiology. The STEP 1 clinical trial showed an average of 14.9% body weight reduction at 68 weeks for participants on FDA-approved branded semaglutide (Wegovy®) 2.4mg weekly. Individual results vary. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products. Understanding the timeline — when to expect results and how they accumulate — helps patients stay motivated through the initial weeks.

Month 1: Starting Dose and Early Changes

Most patients begin semaglutide at 0.25mg weekly for the first 4 weeks — this is a tolerability dose, not a therapeutic dose. Significant weight loss at this stage is not expected. What patients typically experience:

• Reduced appetite and earlier satiety — often noticed within the first 1–2 weeks
• GI adjustment period — nausea, occasional vomiting, and bowel changes are common
• Improved blood sugar stability reported by patients with type 2 diabetes
• Dose escalates to 0.5mg at the end of month 1

Months 2–3: Therapeutic Dose and Momentum

By month 2, most patients are at 0.5mg–1.0mg weekly. This is when meaningful weight loss typically begins. The appetite suppression becomes more pronounced and consistent:

• Food noise (intrusive thoughts about food) dramatically reduces for most patients
• Energy begins improving as the body adapts to the lower calorie intake
• Many patients report this period as transformative — the relationship with food changes fundamentally
• GI side effects typically begin subsiding by week 8–10

Months 4–6: Accelerated Loss and Lifestyle Optimization

Months 4–6 represent the period of most rapid weight loss for many patients, as doses reach therapeutic levels (1.7mg–2.4mg) and lifestyle adaptations compound the medication's effects:

• Patients typically notice significant changes in physical appearance and clothing fit
• Exercise capacity improves as weight decreases — creating a positive feedback loop
• Many patients reach the full 2.4mg dose by this stage

Months 7–12: Approaching Peak Effect

The STEP 1 trial showed continued weight loss through 68 weeks, with most loss occurring in the first year. By 12 months on full-dose semaglutide:

• Weight loss typically plateaus around months 12–16 at maximum effect
• Psychological relationship with food and body image often transforms significantly

Factors That Influence Your Results

The clinical trial averages are just that — averages. Individual results vary significantly based on:

• Dose achieved — patients who reach and maintain 2.4mg lose significantly more weight than those who plateau at lower doses due to side effects
• Starting BMI — patients with higher starting BMIs tend to lose more absolute weight
• Diet quality — protein intake and overall food quality amplify the medication's effects
• Exercise — resistance training preserves muscle mass and improves body composition outcomes
• Sleep and stress management — both directly impact cortisol and metabolic rate
• Consistency of weekly injection timing — irregular dosing reduces efficacy
• Alcohol consumption — alcohol blunts the medication's appetite-suppressing effects

What Happens If You Stop Semaglutide?

This is one of the most important questions for prospective patients. The STEP 4 trial showed that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight within one year. This is not a personal failure — it reflects the biological reality that obesity is a chronic disease requiring ongoing management. Semaglutide works as long as you take it, much like blood pressure medication controls hypertension only while being taken. Your Cora provider can help you develop a long-term maintenance strategy.